Literature DB >> 30773213

Antibiotic use in prevention of anal fistulas following incision and drainage of anorectal abscesses: A systematic review and meta-analysis.

Valentin Mocanu1, Jerry T Dang2, Farah Ladak3, Chunhong Tian4, Haili Wang5, Daniel W Birch6, Shahzeer Karmali7.   

Abstract

BACKGROUND: Treatment of anorectal abscesses continues to revolve around early surgical drainage and control of perianal sepsis. Yet even with prompt drainage, abscess recurrence and postoperative fistula formation rates are as high as 40% within 12 months. These complications are thought to be associated with inadequate drainage, elevated bacterial load, or a noncryptoglandular etiology of disease. Postoperative antibiotics have been used to account for these limitations, but their use is controversial and only weakly supported by current guidelines due to low-quality evidences. The aim of the present study was to perform a systematic review and meta-analysis of the current literature to determine the role of antibiotics in prevention of anal fistula following incision and drainage of anorectal abscesses.
METHODS: Literature search was conducted using Medline, EMBASE, Scopus, the Cochrane Library, and Web of Science databases from 1946 to April 2018. Search terms were "perianal OR anal OR fistula-in-ano OR ischiorectal OR anorectal AND abscess AND antibiotics" and was limited to human studies in the English language. Literature review and data extraction were completed using PRISMA guidelines. A total of six studies with 817 patients were included for systematic review. The weighted mean age was 37.8 years, 20.4% of patients were female, and the follow up ranged from one to 30 months. Antibiotic courses varied by study, and duration ranged from five to 10 days. Of included patients, 358 (43.8%) underwent management without antibiotics while 459 (56.2%) patients were treated with antibiotics. Fistula rate in subjects receiving antibiotics was 16% versus 24% in those not receiving postoperative antibiotics. Meta-analysis revealed a statistically significant protective effect for antibiotic treatment (3 studies, OR 0.64; CI 0.43-0.96; P = 0.03).
CONCLUSIONS: Antibiotic therapy following incision and drainage of anorectal abscesses is associated with a 36% lower odds of fistula formation. An empiric 5-10-day course of antibiotics following operative drainage may avoid the morbidity of fistula formation in otherwise healthy patients, although quality of evidence is low. Further randomized trials are needed to fully clarify the role, duration, and type of antibiotics best suited for postoperative prevention of fistula following drainage of anorectal abscesses.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 30773213     DOI: 10.1016/j.amjsurg.2019.01.015

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  9 in total

Review 1.  Treatments for the amelioration of persistent factors in complex anal fistula.

Authors:  Daniel P Fitzpatrick; Carmel Kealey; Damien Brady; Martin Goodman; Noel Gately
Journal:  Biotechnol Lett       Date:  2021-11-19       Impact factor: 2.461

Review 2.  Anorectal emergencies: WSES-AAST guidelines.

Authors:  Antonio Tarasconi; Gennaro Perrone; Justin Davies; Raul Coimbra; Ernest Moore; Francesco Azzaroli; Hariscine Abongwa; Belinda De Simone; Gaetano Gallo; Giorgio Rossi; Fikri Abu-Zidan; Vanni Agnoletti; Gianluigi de'Angelis; Nicola de'Angelis; Luca Ansaloni; Gian Luca Baiocchi; Paolo Carcoforo; Marco Ceresoli; Alain Chichom-Mefire; Salomone Di Saverio; Federica Gaiani; Mario Giuffrida; Andreas Hecker; Kenji Inaba; Michael Kelly; Andrew Kirkpatrick; Yoram Kluger; Ari Leppäniemi; Andrey Litvin; Carlos Ordoñez; Vittoria Pattonieri; Andrew Peitzman; Manos Pikoulis; Boris Sakakushev; Massimo Sartelli; Vishal Shelat; Edward Tan; Mario Testini; George Velmahos; Imtiaz Wani; Dieter Weber; Walter Biffl; Federico Coccolini; Fausto Catena
Journal:  World J Emerg Surg       Date:  2021-09-16       Impact factor: 5.469

3.  Regular Low-Dose Oral Metronidazole Is Associated With Fewer Vesicovaginal and Rectovaginal Fistulae in Recurrent Cervical Cancer: Results From a 10-Year Retrospective Cohort.

Authors:  Reena George; Thotampuri Shanthi Prasoona; Ramu Kandasamy; Thenmozhi Mani; Shakila Murali; Roja Rekha; Jayaprakash Muliyil
Journal:  J Glob Oncol       Date:  2019-09

4.  Magnetic resonance imaging findings in patients with initial manifestations of perianal fistulas.

Authors:  Khawaja Bilal Waheed; Waseem Jan Shah; Bilal Altaf; Muhammad Amjad; Fawad Hameed; Sana Wasim; Muhammad Zia UlHassan; Zahra Mohammed Abuabdullah; Selvin Nesaraj Rajamonickam; Zechriah Jebakumar Arulanatham
Journal:  Ann Saudi Med       Date:  2020-02-06       Impact factor: 1.526

5.  Risk for developing perianal abscess in type 1 and type 2 diabetes and the impact of poor glycemic control.

Authors:  Karin Adamo; Ulf Gunnarsson; Katarina Eeg-Olofsson; Karin Strigård; Fredrik Brännström
Journal:  Int J Colorectal Dis       Date:  2020-12-17       Impact factor: 2.571

6.  Drug resistant bacteria in perianal abscesses are frequent and relevant.

Authors:  Fabienne Bender; Lukas Eckerth; Moritz Fritzenwanker; Juliane Liese; Ingolf Askevold; Can Imirzalioglu; Winfried Padberg; Andreas Hecker; Martin Reichert
Journal:  Sci Rep       Date:  2022-09-01       Impact factor: 4.996

7.  Non-Locatable Internal Opening in Anal Fistula Associated with Acute Abscess and Its Definitive Management by Garg Protocol.

Authors:  Vipul D Yagnik; Pankaj Garg; Baljit Kaur; Sushil Dawka; Aalam Sohal; Geetha R Menon
Journal:  Clin Exp Gastroenterol       Date:  2022-09-26

8.  Anorectal Abscess in a Patient with Neutropenia and Refractory Acute Myeloid Leukemia: To Operate or not to Operate?

Authors:  Masami Ohzu; Hitomi Takazawa; Satomi Furukawa; Yukiko Komeno
Journal:  Am J Case Rep       Date:  2021-07-04

9.  Learning Curve, Survival Curve.

Authors:  Reena George; Thotampuri Shanthi Prasoona; Ramu Kandasamy; Shakila Murali; Roja Rekha; Thenmozhi Mani
Journal:  JCO Glob Oncol       Date:  2020-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.